Table 3. Outcome of treatment . Before... | American Society of Hematology

Table 3.

Outcome of treatment

	Before CTL evaluation					Fold reduction in EBV load			Outcome at 1 y
Patient	EBV DNA load	PTLD	CTL dose	Toxicity	2 mo after	6 mo after	Clinical	EBV DNA load
1	4 156	No	2 × 10⁷/m²	No	2.3	0.7	Well	1 500
2	136 000	No	2 × 10⁷/m²	No	0.6	3	Well	180 000
3	4 506	No	2 × 10⁷/m²	Transient rise in AST*	2.5	3.7	Well	400
4	16 204	No	5 × 10⁷/m²	No	0.1	1	Well	15 000
5	10 172	No	5 × 10⁷/m²	No	0.4	1.3	Well	3 900
6	6 704	No	5 × 10⁷/m²	No	0.6	10	Well	1 100
7	4 938	No	1 × 10⁸/m²	No	0.9	0.6	Well	3 900
8	14 002	No	1 × 10⁸/m²	No	0.6	0.9	Well	7 200
9	2 500	No	5 × 10⁷/m² × 3	No	1.7	10	Well	7 000
10	1 100	No	5 × 10⁷/m² × 3	No	2.7	10	Well	< 400
11	1 500	No	5 × 10⁷/m² × 4	No	0.4	1.2	Well	700
12	20 900	Eye	5 × 10⁷/m² × 4	No	0.8	3	Well†	25 000

	Before CTL evaluation					Fold reduction in EBV load			Outcome at 1 y
Patient	EBV DNA load	PTLD	CTL dose	Toxicity	2 mo after	6 mo after	Clinical	EBV DNA load
1	4 156	No	2 × 10⁷/m²	No	2.3	0.7	Well	1 500
2	136 000	No	2 × 10⁷/m²	No	0.6	3	Well	180 000
3	4 506	No	2 × 10⁷/m²	Transient rise in AST*	2.5	3.7	Well	400
4	16 204	No	5 × 10⁷/m²	No	0.1	1	Well	15 000
5	10 172	No	5 × 10⁷/m²	No	0.4	1.3	Well	3 900
6	6 704	No	5 × 10⁷/m²	No	0.6	10	Well	1 100
7	4 938	No	1 × 10⁸/m²	No	0.9	0.6	Well	3 900
8	14 002	No	1 × 10⁸/m²	No	0.6	0.9	Well	7 200
9	2 500	No	5 × 10⁷/m² × 3	No	1.7	10	Well	7 000
10	1 100	No	5 × 10⁷/m² × 3	No	2.7	10	Well	< 400
11	1 500	No	5 × 10⁷/m² × 4	No	0.4	1.2	Well	700
12	20 900	Eye	5 × 10⁷/m² × 4	No	0.8	3	Well†	25 000

Two months after CTL infusion.

PTLD decrease in size.